Constellation Pharmaceuticals Inc - Company Profile

Powered by

All the data and insights you need on Constellation Pharmaceuticals Inc in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Constellation Pharmaceuticals Inc Strategy Report

  • Understand Constellation Pharmaceuticals Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Constellation Pharmaceuticals Inc: Overview

Select Item

Constellation Pharmaceuticals Inc (Constellation), a subsidiary of MorphoSys US Inc, is a clinical biopharmaceutical company that focuses on the development of novel therapeutics for the treatment of serious unmet medical needs of patients, especially cancers associated with abnormal gene expression. The company’s pipeline products include pelabresib (CPI-0610) for the treatment of patients with myelofibrosis (MF); CPI-0209 for solid tumors and/or hematological malignancies; and CPI-482 for hematological malignancies. It uses integrated epigenetics platform that enables it to validate targets and generate small molecules against the targets that modulate gene expression in tumor and immune cells. The company has operations in the US. Constellation is headquartered in Cambridge, Massachusetts, the US.

 Gain a 360-degree view of Constellation Pharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of Constellation Pharmaceuticals Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 215 1st St Ste 200, Cambridge, Massachusetts, 02142-1293
Website www.constellationpharma.com
Telephone 1 617 7140555
Industry Pharmaceuticals and Healthcare
   
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Constellation Pharmaceuticals Inc premium industry data and analytics

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Constellation Pharmaceuticals Inc’s relevant decision makers and contact details.

17+

Catalyst Calendar

Proactively evaluate Constellation Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

16+

Pipeline Drugs

Identify which of Constellation Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

10+

Clinical Trials

Determine Constellation Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

5

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Products and Services

Products
Pipeline
Pelabresib (CPI-0610) for Myelofibrosis.
CPI-0209 for solid tumors and/or hematological malignancies.
XYZ
XYZ
XYZ
Understand Constellation Pharmaceuticals Inc portfolio and identify potential areas for collaboration Understand Constellation Pharmaceuticals Inc portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Constellation Pharmaceuticals Inc GSK plc Astellas Pharma Inc Incyte Corp CTI BioPharma Corp
Headquarters United States of America United Kingdom Japan United States of America United States of America
City Cambridge Brentford Chuo-Ku Wilmington Seattle
State/Province Massachusetts England Tokyo Delaware Washington
No. of Employees - 70,212 14,484 2,524 128
Entity Type Private Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Executives
Name Position Board Since Age
Mark A. Goldsmith, M.D., Ph.D. Chairman Executive Board 2017 59
Jigar Raythatha President; Director; Chief Executive Officer Executive Board 2017 44
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Constellation Pharmaceuticals Inc key executives to enhance your sales strategy Gain insight into Constellation Pharmaceuticals Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward